Dr. Nadia Haroun, PharmD

Role & Expertise

Dr. Nadia Haroun is Research Director at Remy Peptides, where she leads editorial review across all research articles published on the site. Her work covers GLP-1 receptor agonists, triple-agonist compounds such as retatrutide, and the broader obesity drug pipeline. Her expertise spans peptide analytical chemistry, HPLC purity validation, and clinical trial data interpretation.

Every article published in the Research Library is reviewed under Dr. Haroun’s direction for factual accuracy, proper citation of peer-reviewed sources, and compliance with the site’s editorial policy.

Credentials

• Doctor of Pharmacy (PharmD)
• Specialization in metabolic pharmacology and peptide therapeutics
• 8+ years in pharmaceutical research and regulatory analysis
• Editorial oversight of 81 research articles at Remy Peptides

Coverage Areas

• GLP-1 and multi-receptor agonist pharmacology
• Obesity drug approval timelines and regulatory pathways
• Peptide stability, storage, and analytical verification
• UAE regulatory compliance (MoHAP Circular 17/2022)
• Comparative efficacy data across the metabolic drug pipeline

Editorial Standards

Articles authored by Dr. Haroun follow the standards documented on the Research Standards page, including:

• Primary sourcing from peer-reviewed journals (NEJM, Lancet, Diabetes Care)
• Clinical trial data cited with ClinicalTrials.gov registration numbers
• Regulatory status verified against FDA, EMA, and MoHAP databases
• No therapeutic claims — all content framed for research context
• Regular updates when new trial readouts or regulatory decisions are published